A Safety and Immunology Study of a DNA Trivalent Influenza Vaccine

Completed · Phase 1

Conditions studied: Influenza

In brief

The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given and any effects it may have on subjects' wellbeing. The study will also test the ability of vaccine to cause particular immune responses in the body.

Key facts

Study ID

NCT00375206

Run by

PowderMed

People needed

189

Starts

2006-09-01

Expected to finish

2007-01-01

Last updated by the study team

2007-01-29

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy adult volunteers (women must be of non child-bearing potential)
• Provided written informed consent

You may not qualify if…

• No significant concomitant illness
• No allergy to gold
• No immunosuppression due to disease or treatment
• No previous flu vaccination in 2005 or 2006

Where it is running

• Quintiles Lenexa (QLX) — Lenexa, Kansas, United States
• Biokinetic — Springfield, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.